Harnessing N-Methyl-D-Aspartate receptors for new treatment development in psychiatry: Positive lessons from negative studies

American Journal of Psychiatry

Volumn 170, Issue 7, 2013, Pages 699-702

  Javitt, Daniel C ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOSERINE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; PLACEBO;

AMYGDALOID NUCLEUS; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; BRAIN FUNCTION; BRAIN NERVE CELL; CELL ACTIVITY; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONDITIONING; DEPRESSION; DESENSITIZATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME REGULATION; FEAR; FOLLOW UP; HUMAN; LOW DRUG DOSE; MEMORY; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NUMBERS NEEDED TO TREAT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHIATRIC TREATMENT; PSYCHOSIS; RECEPTOR BLOCKING; REINFORCEMENT; REVIEW; SINGLE DRUG DOSE; SOCIAL PHOBIA; TREATMENT OUTCOME;

EID: 84883152639     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.13040503     Document Type: Review

References (11)

1. Hofmann SG, Smits JAJ, Rosenfield D, Simon N, Otto MW, Meuret AE, Marques L, Fang A, Tart C, Pollack MH: DCycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry 2013; 170: 751-758
2. Javitt DC: Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9: 984-997, 979
3. Javitt DC, Zukin SR: The role of excitatory amino acids in neuropsychiatric illness. J Neuropsychiatry Clin Neurosci 1990; 2: 44-52
4. Norberg MM, Krystal JH, Tolin DF: A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118-1126
5. Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, Kremer I: A randomized add-on trial of highdose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013; 16: 501-506
6. Kantrowitz J, Javitt DC: Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 2012; 25: 96-102
7. Parnas AS, Weber M, Richardson R: Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 2005; 83: 224-231
8. Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF: Once-weekly Dcycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106: 320-327
9. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S: Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009; 3:CD007954
10. Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM: Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011; 3: 102mr2
11. Hattingh CJ, Ipser J, Tromp SA, Syal S, Lochner C, Brooks SJ, Stein DJ: Functional magnetic resonance imaging during emotion recognition in social anxiety disorder: an activation likelihood meta-analysis. Front Hum Neurosci 2012; 6: 347